Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

EU: Transiting through legal uncertainty? – Economic Times reports ‘Letter of Understanding’ between EU and India (Spicy IP) (Generic Pharmaceuticals and IP)

France considers paralysing IP rights on the appearance of generic drugs (Class 46)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Like-minded group requests convening of WIPO diplomatic conference on genetic resources, traditional knowledge and folklore (KEI)

WHO enters next phase of global plan to increase flu vaccine production (IP Watch)

Neglected diseases R&D financing proposals shaping up at WHO (IP Watch)

Australia: Why the Gene Patents Bill will not work (Patentology)

Australia: Australian scientists threatened, as quality of debate slumps (Patentology)

EU: AG Trstenjak delivers opinion concerning SPC protection and multiple active ingredient, multi-disease vaccines / Medeva v Comptroller-General of Patents (Pertactin and FHA, Gardasil, Cervarix) (EPLAW)

EU: Medeva and Georgetown: AG’s Opinion published today: Medeva BV v Comptroller-General of Patents, Designs and Trade Marks and C‑422/10 Georgetown University, University of Rochester and Loyola University of Chicago v Comptroller-General of Patents, Designs and Trade Marks (SPC blog)

EU: EPO – Danisco v Novozymes continued – Oppositions Division, District Court of The Hague arrive at opposite conclusions – both decisions to be appealed (EPLAW)

EU: Transiting through legal uncertainty? – Economic Times reports ‘Letter of Understanding’ between EU and India (Spicy IP) (Generic Pharmaceuticals and IP)

France considers paralysing IP rights on the appearance of generic drugs (Class 46)

India: Application of Orphan Drug Act to section 3(d)? (Spicy IP)

US: Multicell Technologies receives stem cell patent (Patent Docs)

US: FDA’s NDI guidance and the 18-year cycle of correcting regulatory overreach (FDA Law Blog)

 

Products

Adenoscan (Adenosine) – US: Astellas settles Adenoscan patent suit with Sagent and Strides Arcolab (Patent Docs)

Angiomax (Bivalirudin) – US: The MDCO PTE decision: In play on Capitol Hill and in action at the PTO (FDA Law Blog)

Cipralex (Escitalopram) – Austria: SPCs and Escitalopram in Austria: a correction concerning Supreme Court ruling (The SPC Blog) (The SPC Blog)

Coenzyme Q10 – US: ITC institutes investigation (337-TA-790) regarding certain Coenzyme Q10 products following complaint lodged by Kaneka Corporation (ITC 337 Law Blog)

Fentora (Fentanyl) – Court dismisses, on ripeness grounds, Cephalon challenge to generic Fentora approval (FDA Law Blog)

Glucoamyl L 706+ and Glucoamyl LG20  – US: Novozymes asserts Glucoamylase patents against enzyme distributor: Novozymes v CTE Global (Green Patent Blog)

Lyrica (Pregabalin) – US: Pfizer files patent infringement complaint against Apotex in response to Para IV certification (Patent Docs)

Lysteda (Tranexamic) – US: Ferring files patent infringement complaint against Apotex in response to Para IV certification filing (Patent Docs)

MiraLAX (Polyehtylene glycol 3350) – US: Drug wholesalers secure injunction blocking Braintree from terminating MiraLAX supply (Patent Docs)

Neupogen (Filgrastim), Neulasta (Pegfilgrastim) – US: Teva, Amgen reach settlement on copies of Neupogen, Neulasta (GenericsWeb)

Neutrokine-α – UK: Now on a screen near YOU!: Supreme Court hearing Human Genome Sciences Inc v Eli Lilly and Company (IPKat)

Nexium (Esomeprazole) – UK: EWHC: Ranbaxy wins declaration of non-infringement: Ranbaxy v AstraZeneca (IPKat)

Olanzapine – Spain: Supreme Court hands down landmark judgment on doctrine of equivalents and TRIPS (Kluwer Patent Blog)

OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs)

Prevacid (Lansoprazole) – US: Takeda agrees to drop Mylan from Prevacid patent litigation, but Mylan subsidiary remains (Patent Docs)

Prilosec (Omeprazole) – Canada: Issue estoppel and foreign proceedings: Astrazeneca Canada v Apotex (Sufficient Description)

Restoril (Temazepam) – US: CAFC finds low-dose product claims obvious over medical reference book: Tyco Healthcare v Mutual Pharmaceuticals (Pharma Patents) (Orange Book Blog)

Seroplex (Escitalopram) – France: English translation of Escitalopram patent and SPC decision handed down by Tribunale de Grande Instance de Paris (The SPC Blog)

Simcor (Niacin, Simvastatin) – US: Abbott Laboratories files patent infringement complaint against Watson Pharmaceuticals in response to Para IV certification (Patent Docs)

Spezyme (Thermostable alpha-amylase products) – US: W D Wisconsin rules that Genencor products infringe Novozymes patent (Holman’s Biotech IP Blog)

Vyvanse (Lisdexamfetamine) – US: Shire files patent infringement complaint against Watson following Para IV certification filing (Patent Docs)

Zyprexa (Olanzapine) – UK: EWHC stays Olanzapine infringement/invalidity action pending payment into court: Eli Lilly & Co v Neopharma and Gurnos (PatLit)